Enliven Therapeutics Prices $400M Offering
Analysis based on 9 articles · First reported Jun 11, 2026 · Last updated Jun 12, 2026
The public offering by Enliven Therapeutics is expected to generate approximately $400.0 million in gross proceeds, providing significant capital for the company's operations and drug development. This influx of capital could positively impact Enliven Therapeutics' stock price and its ability to advance its clinical-stage programs, potentially leading to future growth in the biotechnology sector.
Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of its upsized underwritten public offering. The offering includes 8,933,334 shares of common stock at $37.50 per share and 1,733,333 pre-funded warrants at $37.499 per warrant. The gross proceeds are expected to be approximately $400.0 million. The offering is anticipated to close around June 15, 2026, subject to customary closing conditions. Enliven Therapeutics has also granted the underwriters a 30-day option to purchase an additional 1,600,000 shares of common stock. Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays are acting as joint book-running managers, with Mizuho and LifeSci Capital as book-running managers, and Baird (investment bank) and Jones as managers. The offering is being made pursuant to a registration statement filed with the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard